Tags : IL-23

Janssen (J&J) Expands its PTG-200 Collaboration with Protagonist for Second

Shots: Protagonist to receive $25M upfront, $1.0B as development, regulatory & commercial milestones & royalties on product sales with rights to co-detail both products. Janssen to get exclusive WW rights to develop & commercialize both candidates and will pay certain costs and milestones for advancing preclinical candidates through P-I In 2017, the companies entered into […]Read More